About
Viridian Therapeutics
VRDN.US
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED.
Profile
- Company Name
- Viridian Therapeutics, Inc.
- Market
- NasdaqCM
- Founded
- Industry
- --
- Fiscal Year End
- December 31
- Website
- www.viridiantherapeutics.com